Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs (Q38260862)

1 September 2017

1 reference

title

Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs (English)

1 reference

1 September 2017

Jill M Steinbach

1

1 reference

1 September 2017

publication date

17 October 2014

1 reference

Cellular and Molecular Life Sciences

1 September 2017

published in

1 reference

1 September 2017

volume

72

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

469-503

1 reference

Vaginal drug delivery systems for HIV prevention

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Advances in microbicide vaginal rings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

New concepts in herpes simplex virus vaccine development: notes from the battlefield

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Rapid host immune response and viral dynamics in herpes simplex virus-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Herpes Simplex: Insights on Pathogenesis and Possible Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Interventions against sexually transmitted infections (STI) to prevent HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Development of topical microbicides to prevent the sexual transmission of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Microbicides for the prevention of sexually transmitted HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The acceptability of the female and male condom: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Challenges and Successes in Linking HIV-Infected Women to Care in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

An overview of sexually transmitted diseases. Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The development of vaginal microbicides for the prevention of HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

HIV prevention transformed: the new prevention research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The challenge of developing a herpes simplex virus 2 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antibodies in HIV-1 vaccine development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Development of prophylactic vaccines against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Microbicides and other topical strategies to prevent vaginal transmission of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Microbicide research: current and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Dual purpose contraceptives: targeting fertility and sexually transmitted disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Dual action microbicides: reappraisal of their roles in contraceptive research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

RNA-based therapeutics: current progress and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Interfering with disease: opportunities and roadblocks to harnessing RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Advancements in the field of intravaginal siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The vagina as a route for systemic drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mucoadhesive vaginal tablets as veterinary delivery system for the controlled release of an antimicrobial drug, acriflavine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Safety and immunogenicity of intramuscular and intravaginal delivery of HIV‐1 DNA constructs to infant chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Vaginal absorption of insulin in the rat: effect of penetration enhancers on insulin uptake and mucosal histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human cervical mucus: Research update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human cervicovaginal mucus contains an activity that hinders HIV-1 movement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mathematical modeling of molecular diffusion through mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Micro- and macrorheology of mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Nanoparticle-based vaginal drug delivery systems for HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

HIV gp120 binds to mannose receptor on vaginal epithelial cells and induces production of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Setting the stage: host invasion by HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

HIV binding, penetration, and primary infection in human cervicovaginal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A role for heparan sulfate in viral surfing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A pooled analysis of the effect of condoms in preventing HSV-2 acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Transcytosis of HIV-1 through vaginal epithelial cells is dependent on trafficking to the endocytic recycling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antibody diffusion in human cervical mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Barriers to mucosal transmission of immunodeficiency viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Drug delivery: Stealth particles give mucus the slip

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Vaginal rings for delivery of HIV microbicides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Barrier properties of mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Lessons from nature: "Pathogen-Mimetic" systems for mucosal nano-medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The use of mucoadhesive polymers in vaginal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Pharmaceutical development of microbicide drug products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Vaginal ring adherence in sub-Saharan Africa: expulsion, removal, and perfect use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Acceptability and use of sexual barrier products and lubricants among HIV-seropositive Zambian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The last decade of microbicide clinical trials in Africa: from hypothesis to facts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Chitosan gels for the vaginal delivery of lactic acid: relevance of formulation parameters to mucoadhesion and release mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Smart polymer based delivery systems for peptides and proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Bioadhesive-based dosage forms: the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mucoadhesive vaginal drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Design properties of hydrogel tissue-engineering scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Hydrogels in pharmaceutical formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mucoadhesive drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Water dispersible microbicidal cellulose acetate phthalate film

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Development of a system for simultaneous dissolution studies and magnetic resonance imaging of water transport in hydrodynamically balanced systems: a technical note

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Vaccine delivery by polymeric vehicles in the mouse reproductive tract induces sustained local and systemic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Nanoparticle delivery of cancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Nanoparticles as drug delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Virostatic potential of micro-nano filopodia-like ZnO structures against herpes simplex virus-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

PLGA nanoparticles in drug delivery: the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

PLGA-based nanoparticles: an overview of biomedical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Early Events in Sexual Transmission of HIV and SIV and Opportunities for Interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Glycerol monolaurate prevents mucosal SIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Polymeric controlled delivery for immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Monoclonal antibodies for reproductive health: Part I. Preventing sexual transmission of disease and pregnancy with topically applied antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Aptamer-targeted cell-specific RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Peptides derived from salivary thrombospondin-1 replicate its anti-HIV effect: potential role in microbicide development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Protein-based HIV-1 microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antibody-based protection against HIV infection by vectored immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Design, expression, and characterization of a multivalent, combination HIV microbicide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antigen-releasing polymer rings and microspheres stimulate mucosal immunity in the vagina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Engineering mucosal RNA interference in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Neutralizing antibodies to HIV-1 induced by immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Microbicides and HIV prevention: lessons from the past, looking to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Herpes virus fusion and entry: a story with many characters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A vaccine strategy that protects against genital herpes by establishing local memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Chemokines at mucosal barriers and their impact on HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Griffithsin protects mice from genital herpes by preventing cell-to-cell spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Griffithsin has antiviral activity against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

HIV and the chemokine system: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mechanisms of viral membrane fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The Genotype of Early-Transmitting HIV gp120s Promotes α4β7 –Reactivity, Revealing α4β7+/CD4+ T cells As Key Targets in Mucosal Transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Blocking of α4β7 Gut-Homing Integrin during Acute Infection Leads to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency Virus-Infected Rhesus Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A role for 3-O-sulfotransferase isoform-4 in assisting HSV-1 entry and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antimicrobial peptides: The ancient arm of the human immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Structural Analyses of Covalent Enzyme–Substrate Analog Complexes Reveal Strengths and Limitations of De Novo Enzyme Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human alpha-defensins block papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antiviral Peptides Targeting the West Nile Virus Envelope Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Peptide antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antiviral activity of selected antimicrobial peptides against vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Mechanism of an amphipathic alpha-helical peptide's antiviral activity involves size-dependent virus particle lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Novel synthetic, salt-resistant analogs of human beta-defensins 1 and 3 endowed with enhanced antimicrobial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antiviral effects of synthetic membrane-active peptides on herpes simplex virus, type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

The θ-Defensin, Retrocyclin, Inhibits HIV-1 Entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

In vivo gene delivery by nonviral vectors: overcoming hurdles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Aptamer mediated siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Transvascular delivery of small interfering RNA to the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Vaginal DNA vaccination against infectious diseases transmitted through the vagina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Effective vaginal DNA delivery with high transfection efficiency is a good system for induction of higher local vaginal immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Needle-free intravaginal DNA vaccination using a stearoyl oligopeptide carrier promotes local gene expression and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Current progress in the development of RNAi-based therapeutics for HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Whither or wither microbicides?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Drug-eluting fibers for HIV-1 inhibition and contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Electrospun fibers for vaginal anti-HIV drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Progress in siRNA delivery using multifunctional nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Synthetic cervical mucus formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Globular structure of human ovulatory cervical mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-014-1756-3

Decentralising HIV treatment in lower- and middle-income countries

21 January 2018

1 reference

12 December 2020

Transgenic plant production of Cyanovirin-N, an HIV microbicide.

1 reference

12 December 2020

Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication

1 reference

12 December 2020

The pH of cervical mucus and the postcoital test

1 reference

12 December 2020

Antibodies for treating and preventing disease: the potential role of polymeric controlled release.

1 reference

12 December 2020

Protein delivery from nondegradable polymer matrices

1 reference

12 December 2020

Use of monoclonal antibodies in local passive immunization to prevent colonization of human teeth by Streptococcus mutans

1 reference

12 December 2020

Drug delivery by the intravaginal route.

1 reference

12 December 2020

Topical antibody delivery systems produce sustained levels in mucosal tissue and blood

1 reference

12 December 2020

Detection of ovulation

1 reference

12 December 2020

Discontinuation of the clinical development of fusion inhibitor T-1249.

1 reference

12 December 2020

Synergistic copathogens--HIV-1 and HSV-2

1 reference

12 December 2020

Chemokine inhibition of HIV infection

1 reference

12 December 2020

The Induction of Mucosal Immunity in the Female Genital Tract Using Gene-Gun Technology Part 1: Antigen Expression

1 reference

12 December 2020

Immunization of the Female Genital Tract with a DNA-Based Vaccine

1 reference

12 December 2020

Controlled vaginal delivery of antibodies in the mouse

1 reference

12 December 2020

Langerhans cells phagocytose vaginal epithelial cells undergoing apoptosis during the murine estrous cycle

1 reference

12 December 2020

Transmembrane proteins in the tight junction barrier.

1 reference

12 December 2020

Therapeutic siRNA: principles, challenges, and strategies.

1 reference

12 December 2020

Residence half-life of IgG administered topically to the mouse vagina

1 reference

12 December 2020

siRNA-directed inhibition of HIV-1 infection

1 reference

12 December 2020

Long-term vaginal antibody delivery: delivery systems and biodistribution

1 reference

12 December 2020

VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection

1 reference

12 December 2020

Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells

1 reference

12 December 2020

Initial interaction of herpes simplex virus with cells is binding to heparan sulfate

1 reference

12 December 2020

Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol

1 reference

12 December 2020

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

1 reference

12 December 2020

A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus.

1 reference

12 December 2020

Optimizing siRNA delivery to the genital mucosa

1 reference

12 December 2020

Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry

1 reference

12 December 2020

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

1 reference

12 December 2020

Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4.

1 reference

12 December 2020

siRNA-based topical microbicides targeting sexually transmitted infections.

1 reference

12 December 2020

Implementing microbicides in low-income countries

1 reference

12 December 2020

State of the art in intravaginal ring technology for topical prophylaxis of HIV infection.

1 reference

12 December 2020

Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry

1 reference

12 December 2020

Absorption and excretion of undegradable peptides: role of lipid solubility and net charge

1 reference

12 December 2020

Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections

1 reference

12 December 2020

Microbicides: topical prevention against HIV

1 reference

12 December 2020

Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge

1 reference

12 December 2020

New Success With Microbicides and Pre-Exposure Prophylaxis for Human Immunodeficiency Virus (HIV): Is Female-Controlled Prevention the Answer to the HIV Epidemic?

1 reference

12 December 2020

Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site

1 reference

12 December 2020

Emtricitabine/tenofovir (Truvada) for HIV prophylaxis

1 reference

12 December 2020

Solid dispersions: a review

1 reference

12 December 2020

Langerhans' cells and lymphocyte subsets in the female genital tract

1 reference

12 December 2020

Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections

1 reference

12 December 2020

10.1007/S00018-014-1756-3

Identifiers

DOI

1 reference

1 September 2017

1 reference